PO.IM02.03 · 免疫学

肠道共生菌毛螺菌科(Lachnospiraceae)的比较基因组学及其与免疫检查点抑制剂癌症治疗应答的关联

Comparative genomics of gut commensal Lachnospiraceae and their associations with cancer treatment response with immune checkpoint inhibitors

编号 2861 展板 1 时间 4/20 02:00–05:00 区域 Section 9 主讲 Shiva Jahanbakhshi, MS
分会场 Microbiome, Inflammation, and Response to Immunotherapy in Cancer
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Shiva Jahanbakhshi, Amna Bibi, Rebecca Hoyd, Caroline Dravillas, Nyelia Williams, Shiqi Zhang, Aaditya Pallerla, Shankar Suman, Joseph Amann, Mounika Goruganthu, Tamio Okimoto, Yangyang Liu, Marisa A. Bittoni, Ni Shi, Alvin Anand, Bailey Conrad, Lane Nevers, Kristen Heitman, Maxine Webb, Elizabeth M. Grainger, Madison Grogan, Christian Quiles, Tong Chen, Carolyn J. Presley, Lang Li, Patrick Bradley, Yael Vodovotz, David P. Carbone, Steven K. Clinton, Jiangjiang Zhu, Daniel Spakowicz

The Ohio State University, Columbus, OH

摘要 Abstract

中文摘要
免疫检查点抑制剂(ICI)是癌症治疗中的开创性进展,但应答率存在差异。肠道微生物组日益被认为是ICI疗效的一个可调节的决定因素。BEWELL试验实施了一项黑树莓(BRB)花蜜饮食干预,显著富集了结肠微生物组中毛螺菌科成员。当将BRB调节的微生物组转移至小鼠体内时,这些微生物组增强了ICI的抗肿瘤活性,提示特定菌群在塑造治疗应答性中的作用。为研究毛螺菌科改变ICI有效性的机制,我们用BRB富集的密切相关菌株分别补充了小鼠的微生物组:Blautia obeum、Blautia massiliensis和Agathobacter rectalis。在异位小鼠模型中(将1×10⁶个MC38细胞皮下注射至C57BL/6小鼠,每3天用抗PD1或IgG治疗),B. obeum和B. massiliensis改善了ICI的有效性,而A. rectalis则没有。我们比较了这些生物体的基因组,鉴定出177个KEGG直系同源物(ortholog),它们为B. obeum和B. massiliensis所独有共享,但在A. rectalis中缺失。使用KEGGREST映射和clusterProfiler过表达检验进行KO通路分配和富集分析,以所有基因组编码的KO作为背景。我们鉴定出四条与免疫和ICI应答相关的通路:(1)Wood-Ljungdahl通路的关键基因,这是产生乙酸盐(已证明是一种T细胞能量来源)的主要途径(乙酰辅酶A脱羰基酶/合成酶(K00194、K00197、K00198)和推定的磷酸转乙酰酶(K01490));(2)合成对T细胞增殖至关重要的维生素的基因——叶酸(B9)(二氢蝶酸合成酶(K00796)、GTP环化水解酶I(K022391)、亚甲基四氢叶酸还原酶(K00297))和钴胺素(B12)(钴(I)胺素腺苷转移酶(K019221)、类咕啉腺苷转移酶(K0174)、钴胺素还原酶(K0175));(3)L-鼠李糖合成基因,其细胞壁修饰充当微生物相关分子模式,激发先天免疫(dTDP-4-脱氢鼠李糖还原酶(K00067)和dTDP-葡萄糖4,6-脱水酶(K00935));以及(4)将胆汁酸转化为次级异胆汁酸的基因,这些异胆汁酸与宿主受体(FXR、TGR5)相互作用以调节Th17/Treg平衡(3-alpha-羟基胆烷酸脱氢酶(K0164))。总体而言,这些过程与可能影响抗肿瘤免疫的宿主相关代谢和信号环境相契合。我们的研究提示,可以开发新型食品用于人体测试,以增强抗癌免疫治疗。此外,BRB应答性的毛螺菌科拥有富集的代谢和免疫调节基因程序,这可能是其与ICI治疗肿瘤应答改善相关联的基础。
查看英文原文 English abstract
Immune checkpoint inhibitors (ICIs) are seminal advances in cancer therapeutics, yet response rates are variable. The gut microbiome is increasingly recognized as a modifiable determinant of ICI efficacy. The BEWELL trial delivered a black raspberry (BRB) nectar dietary intervention that significantly enriched the colonic microbiome with members of the Lachnospiraceae family. When BRB-modulated microbiomes were transferred into mice, these microbiomes enhanced ICI antitumor activity, implicating specific taxa in shaping therapeutic responsiveness.To investigate the mechanism by which Lachnospiraceae altered ICI effectiveness, we individually supplemented the microbiomes of mice with closely related strains enriched by BRB: Blautia obeum , Blautia massiliensis , and Agathobacter rectalis . In a heterotopic mouse model (1×10⁶ MC38 cells injected subcutaneously into C57BL/6 mice, treated every 3 days with anti-PD1 or IgG), B. obeum and B. massiliensis improved ICI effectiveness, whereas A. rectalis did not. We compared the genomes of these organisms and identified 177 KEGG orthologs uniquely shared by B. obeum and B . massiliensis but absent in A. rectalis . KO pathway assignments and enrichment analyses were conducted using KEGGREST mapping and clusterProfiler overrepresentation testing, with all genome-encoded KOs as the background.We identified four relevant pathways associated with immunity and ICI response: (1) Key genes for the Wood-Ljungdahl pathway, a major route for producing acetate, shown to be a T-cell energy source (acetyl-CoA decarbonylase/synthase (K00194, K00197, K00198) and putative phosphotransacetylase (K01490)); (2) Genes for synthesizing vitamins essential for T-cell proliferation-folate (B9) (dihydropteroate synthase (K00796), GTP cyclohydrolase I (K022391), methylenetetrahydrofolate reductase (K00297)) and cobalamin (B12) (cob(I)alamin adenosyltransferase (K019221), corrinoid adenosyltransferase (K0174), cobalamin reductase (K0175)); (3) L-rhamnose synthesis genes whose cell-wall decorations act as microbe-associated molecular patterns, priming innate immunity (dTDP-4-dehydrorhamnose reductase (K00067) and dTDP-glucose 4,6-dehydratase (K00935)); and (4) Genes converting bile acids to secondary, iso-bile acids that interact with host receptors (FXR, TGR5) to regulate Th17/Treg balance (3-alpha-hydroxycholanate dehydrogenase (K0164)) Collectively, these processes align with host-relevant metabolic and signaling environments that may impact anti-tumor immunity. Our study suggests that novel food products can be developed for human testing to enhance anticancer immunotherapeutics. Furthermore, BRB-responsive Lachnospiraceae possess enriched metabolic and immunomodulatory gene programs that may underlie their association with improved tumor response to ICI treatment.
利益披露 Disclosure
S. Jahanbakhshi, None.. A. Bibi, None.. R. Hoyd, None.. C. Dravillas, None.. N. Williams, None.. S. Zhang, None.. A. Pallerla, None.. S. Suman, None.. J. Amann, None.. M. Goruganthu, None.. T. Okimoto, None.. Y. Liu, None.. M. A. Bittoni, None.. N. Shi, None.. A. Anand, None.. B. Conrad, None.. L. Nevers, None.. K. Heitman, None.. M. Webb, None.. E. M. Grainger, None.. M. Grogan, None.. C. Quiles, None.. T. Chen, None.. C. J. Presley, None.. L. Li, None.. P. Bradley, None.. Y. Vodovotz, None.. D. P. Carbone, None.. S. K. Clinton, None.. J. Zhu, None.. D. Spakowicz, None.

← 返回 AACR 2026 检索